UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds

27th February 2026 Uncategorised 0

Two years and five indications later, UCB’s immunology blockbuster Bimzelx is halfway to the company’s initial goal of at least 4 billion euros ($4.4 billion) in peak sales.

More: UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds
Source: fierce